Loading...
01/11 03:18
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals a concerning financial performance with a widening net loss and increased expenses due to commercialization activities. The Q&A highlighted uncertainties about payer coverage and formulary approvals, which are crucial for future sales. While there is positive physician feedback, the limited current coverage and the lack of detailed guidance on key metrics contribute to a negative outlook. The stock is likely to react negatively in the short term due to these uncertainties and financial pressures.
Net Product Revenues $0.4 million in the third quarter of 2025, driven by the launch of ORLYNVAH in August 2025, including initial stocking at specialty pharmacies.
Total Operating Expenses $8.1 million in Q3 2025, up from $4.9 million in Q3 2024, a 65% increase year-over-year. The increase was primarily due to commercialization activities for ORLYNVAH.
Cost of Sales $0.02 million in Q3 2025, primarily consisting of royalty payments to Pfizer. Prior to FDA approval in October 2024, manufacturing costs were recorded as R&D expenses.
Amortization of Intangible Assets $0.3 million in Q3 2025, related to regulatory milestone payments to Pfizer upon FDA approval of ORLYNVAH.
Research and Development (R&D) Costs $1.3 million in Q3 2025, down from $3.1 million in Q3 2024, a 58% decrease year-over-year. The decrease was due to lower chemistry manufacturing and control (CMC)-related expenses.
Selling, General, and Administrative (SG&A) Costs $6.5 million in Q3 2025, up from $1.8 million in Q3 2024, a 261% increase year-over-year. The increase was driven by commercialization activities for ORLYNVAH.
Net Loss (GAAP) $9 million in Q3 2025, compared to $6.1 million in Q3 2024, a 48% increase year-over-year. The increase was primarily due to commercialization activities for ORLYNVAH.
Net Loss (Non-GAAP) $7.3 million in Q3 2025, compared to $4.8 million in Q3 2024, a 52% increase year-over-year. The increase was primarily due to commercialization activities for ORLYNVAH, partially offset by lower CMC-related expenses.
Cash and Cash Equivalents $11 million as of the end of September 2025. Combined with $2.6 million raised through an at-the-market offering program, the funds are expected to support operations into Q2 2026.
ORLYNVAH Launch: ORLYNVAH was launched in the U.S. market on August 20, 2025. Over 280 prescriptions have been generated by more than 100 unique prescribers, with nearly half prescribing to multiple patients. Approximately 40% of prescriptions have been filled through payer approval processes.
Specialty Distribution: ORLYNVAH is now available through specialty distributors McKesson and Syncora to accommodate physicians' practice models.
Physician Feedback: Physicians value ORLYNVAH as an alternative for treating uncomplicated urinary tract infections, especially where resistance is a challenge. It helps keep patients out of hospitals and provides a new oral treatment option.
Market Access: Coverage discussions with pharmacy benefit managers and health plans are advancing. A rebate agreement with a top 3 Medicare Part D pharmacy benefit manager has been signed, enabling coverage starting in 2026 or 2027. ORLYNVAH currently reaches 16% of insured lives.
Geographic Expansion: Iterum plans to expand into high-value territories and increase resources in existing geographies, contingent on raising additional capital.
Sales Force Optimization: The in-person field team was reduced from 20 to 10 representatives, supplemented by virtual sales representatives to maintain coverage in 20 target geographies with greater efficiency.
Financial Performance: Net product sales for Q3 2025 were $400,000. Operating expenses for 2026 are estimated at $25-$30 million, with cash runway into Q2 2026. Additional capital is required to sustain operations.
Patent Expansion: New patents were granted in China and Mexico, covering specific formulations and methods, with expirations in 2041 and 2039, respectively.
Capital Raising: Iterum plans to seek shareholder approval to issue additional shares to raise capital for continued commercialization and expansion efforts.
Commercialization Challenges: The company faces challenges in changing long-standing prescribing habits among healthcare providers, which requires frequent office visits and consistent messaging. Additionally, the modest commercial infrastructure limits the ability to scale operations effectively.
Payer Coverage and Reimbursement: A significant portion of prescriptions (60%) are not yet covered by payers, leading to delays in patient access and potential financial barriers. The company is still in the process of securing broader payer coverage, including Medicare plans, which is critical for long-term success.
Financial Sustainability: The company has limited cash reserves, sufficient only until Q2 2026, and has yet to secure additional funding. This creates uncertainty around the ability to sustain operations and continue commercialization efforts.
Market Penetration: Despite initial progress, the company has only reached 16% of insured lives, indicating limited market penetration. This could hinder revenue growth and broader adoption of ORLYNVAH.
Operational Efficiency: The reduction of the in-person field team from 20 to 10 representatives and reliance on virtual sales representatives may impact the effectiveness of sales efforts in key geographies.
Regulatory and Competitive Risks: The company is dependent on ongoing patent protections and faces potential competition from other antibiotic treatments, which could impact market share and revenue.
2026 Net Product Sales: Expected to be in the range of $5 million to $15 million, driven by the commercialization of ORLYNVAH in the U.S. and expansion into new territories.
Operating Expenses for 2026: Estimated to be between $25 million and $30 million for the full year.
Cash Resources: Current cash and cash equivalents are expected to fund operations into Q2 of 2026. Additional capital will be required to continue commercialization efforts throughout 2026.
Capital Raising Plans: Plans to raise additional capital through shareholder approval for issuing more shares or exploring non-dilutive funding options.
Market Access and Payer Coverage: Positive feedback from pharmacy benefit managers and health plans. Signed rebate agreement with a top 3 Medicare Part D pharmacy benefit manager for coverage starting in 2026 or 2027. Coverage currently reaches 16% of insured lives, with expectations for further decisions in upcoming quarters.
Expansion Plans: Plans to expand into high-value territories and increase resources in existing geographies if additional capital is raised.
Patent Protection: New patents granted in China and Mexico, with expirations in 2041 and 2039 respectively, covering specific formulations and methods for ORLYNVAH.
The selected topic was not discussed during the call.
The earnings call reveals a concerning financial performance with a widening net loss and increased expenses due to commercialization activities. The Q&A highlighted uncertainties about payer coverage and formulary approvals, which are crucial for future sales. While there is positive physician feedback, the limited current coverage and the lack of detailed guidance on key metrics contribute to a negative outlook. The stock is likely to react negatively in the short term due to these uncertainties and financial pressures.
The earnings call presents a mixed picture. Financial performance shows improvement with reduced losses and operating expenses, which is positive. However, the lack of clarity on partnerships and the need for capital raising post-launch are concerning. The absence of a share repurchase program and competition risks further dampen sentiment. Despite projected sales potential, uncertainties in commercialization plans and strategic alternatives evaluation create a balanced outlook, suggesting a neutral stock price movement in the short term.
The earnings call highlights significant risks, including going concern issues, capital raising challenges, and uncertainties about market acceptance. Despite reduced operating expenses and net losses, the company's financial health remains precarious due to a deferred $20 million payment to Pfizer accruing interest. The lack of clear guidance on strategic partnerships further exacerbates concerns. The Q&A section reveals management's evasiveness, which may increase investor apprehension. Given these factors, the stock price is likely to face a negative reaction over the next two weeks.
The earnings call presents a mixed outlook. Financial performance shows reduced operating expenses and net loss, but there's a significant cash flow risk due to outstanding exchangeable notes and deferred milestone payments. The Q&A reveals strategic uncertainties and limited clarity on future partnerships. The lack of European patents and the need for additional studies in key markets like China and Japan further complicate the outlook. Despite a promising label for ORLYNVAH, these factors balance out, suggesting a neutral stock price movement over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
